Injection scheme for intravitreal bevacizumab therapy for macular oedema due to central retinal vein occlusion: Results of a multicenter study

Acta Ophthalmologica

Volumn 94, Issue 1, 2016, Pages e80-e81

  Cəlugəru, Dan ^a   Cəlugəru, Mihai ^a  

^a IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN ANTIBODY; ANGIOGENESIS INHIBITOR;

CENTRAL RETINA ARTERY OCCLUSION; CLINICAL EFFECTIVENESS; EMERGENCY TREATMENT; EVIDENCE BASED PRACTICE; HUMAN; LETTER; MACULAR EDEMA; MULTICENTER STUDY (TOPIC); NEOVASCULAR GLAUCOMA; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; COMPLICATION; RETINA VEIN OCCLUSION;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; HUMANS; MACULAR EDEMA; RETINAL VEIN OCCLUSION;

EID: 84955657633     PISSN: 1755375X     EISSN: 17553768     Source Type: Journal    
DOI: 10.1111/aos.12793     Document Type: Letter

References (4)

1. Cəlugəru D, &, Cəlugəru M, (2015): Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study. Journal of Ocular Pharmacology- and Therapeutics 31: 78-86.
2. Epstein DLJ, Algvere PV, von Wendt G, Seregard S, &, Kvanta A, (2012a): Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinicalstudy. Ophthalmology 119: 1184-1189.
3. Epstein DLJ, Algvere PV, von Wendt G, Seregard S, &, Kvanta A, (2012b): Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective randomized study. Ophthalmology 119: 2587-2591.
4. Januschowski K, Dimopoulos S, Szurman P, et al., (2015): Injection scheme for intravitreal bevacizumab therapy for macular edema due to central retinal vein occlusion: results of a multicenter study. Acta Ophthalmol. 93: e400-e402.